Modern Healthcare: Drugs imported by states under the Trump administration's importation plan will not be subject to Medicaid rebates, which means they would not set new 340B prices according to CMS guidance released Friday.
The state guidance calls into question whether states will be able to save significant amounts of money through Medicaid buying imported drugs compared with the large statutory rebates already conferred by the Medicaid rebate program. The Medicaid rebate program also determines 340B ceiling prices, so any potential state importation programs would be excluded from factoring into those prices.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now